Expertise in

conditions

Mohamad Mohty

Paris, FR

Expertise in

conditions

Paris, FR

Overview

Mohamad Mohty practices practicing medicine in Paris, France.

Mr. Mohty is highly rated in 28 conditions, according to our data. His clinical expertise encompasses Graft Versus Host Disease (GvHD), Leukemia, Acute Myeloid Leukemia (AML), Bone Marrow Transplant, and Bone Graft.

He is actively involved in clinical research, co-authoring 1055 peer reviewed articles and participating in 9 clinical trials.

Gender

Male

Locations

Paris, France

Other Locations

Saint Antoine, France

Toulouse, France

Vitry-sur-seine, France

Bordeaux, France

Marseille, France

Nantes, France

Lyon, France

Besancon, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Phase III, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Single Agent Belantamab Mafodotin Compared to Pomalidomide Plus Lowdose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) (DREAMM 3)

Enrollment Status: Active_not_recruiting

Publish Date: July 01, 2026

Intervention Type: Drug

Study Drugs: Belantamab Mafodotin, Pom/Dex (Pomalidomide plus Low Dose Dexamethasone)

Study Phase: Phase 3

A Phase II Trial Evaluating Glofitamab, a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas After CAR T-cells Therapy

Enrollment Status: Completed

Publish Date: March 16, 2026

Intervention Type: Drug

Study Drugs: Obinutuzumab, RO7082859

Study Phase: Phase 2

A Phase 1/2 Open-label Study to Investigate the Safety and Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Modakafusp Alfa (TAK-573) as a Single Agent in Patients With Relapsed Refractory Multiple Myeloma

Enrollment Status: Terminated

Publish Date: January 29, 2026

Intervention Type: Drug

Study Drugs: TAK-573, Dexamethasone

Study Phase: Phase 1/Phase 2

Studyof Allogeneic Hematopoietic Stem Cell Transplantation From One Haplotype Mismatch Related Donor or From an Unrelated Donor in Elderly Patients

Enrollment Status: Completed

Publish Date: January 31, 2023

Intervention Type: Biological

Study Phase: Phase 3

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) Plus Low-Dose Dexamethasone (Sd) in Patients With Multiple Myeloma Previously Treated With Lenalidomide, Pomalidomide, Bortezomib, Carfilzomib, and an Anti-CD38 Monoclonal Antibody (mAb) Daratumumab, and Refractory to Prior Treatment With Glucocorticoids, an Immunomodulatory Agent, a Proteasome Inhibitor, and an the Anti-CD38 mAb Daratumumab

Enrollment Status: Completed

Publish Date: January 26, 2023

Intervention Type: Drug

Study Phase: Phase 2

A Phase 3, Randomized, Adaptive Study Comparing the Efficacy and Safety of Defibrotide vs Best Supportive Care in the Prevention of Hepatic Veno-Occlusive Disease in Adult and Pediatric Patients Undergoing Hematopoietic Stem Cell Transplant

Enrollment Status: Completed

Publish Date: March 02, 2022

Intervention Type: Other, Drug

Study Phase: Phase 3

A Phase 3, Multicenter, Randomized, Open-label, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment With Ganciclovir, Valganciclovir, Foscarnet, or Cidofovir

Enrollment Status: Completed

Publish Date: November 03, 2021

Intervention Type: Drug

Study Phase: Phase 3

A Multi-centre, Multinational, Prospective Observational Registry to Collect Safety and Outcome Data in Patients Diagnosed With Severe Hepatic Veno-occlusive Disease (VOD) Following Hematopoietic Stem Cell Transplantation (HSCT) and Treated With Defitelio®

Enrollment Status: Completed

Publish Date: October 16, 2019

Phase 2 Study of a Reduced-toxicity Myeloablative Conditionning Regimen Using Fludarabine and Full Doses of iv Busulfan in Pediatric Patients Not Eligible for Standard Myeloablative Conditioning Regimens

Enrollment Status: Completed

Publish Date: April 05, 2018

Intervention Type: Drug

Study Phase: Phase 2

View 8 Less Clinical Trials

1055 Total Publications

GPRC5D CAR-T: a new path beyond BCMA.

Journal: Blood

Published: September 03, 2026

View All 1055 Publications

Frequently Asked Questions about Mohamad Mohty

Is Mohamad Mohty a top-rated expert for Graft Versus Host Disease (GvHD)?

MediFind is an objective health platform that identifies experts based on real-world data. Mohamad Mohty is classified as an Elite expert for Graft Versus Host Disease (GvHD), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Mohamad Mohty participate in research or clinical trials?

Yes. Mohamad Mohty has published 1055 articles and abstracts on conditions like Graft Versus Host Disease (GvHD). You can view a list of Mohamad Mohty's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Mohty's expertise for a condition

ConditionClose